EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress

SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B , and...

Related Keywords

Spain ,Australia ,Rockville ,Pennsylvania ,United States ,China ,Madrid ,Nanfang ,Guangdong ,Florida ,Hong Kong ,Peking ,Beijing ,Texas ,Suzhou ,Jiangsu ,Philadelphia ,Lu Yu ,Sikander Ailawadhi ,Ascentage Pharma ,Yifan Zhai ,Junjie Chen ,Prnewswire Ascentage Pharma ,Southern Medical University ,European Hematology Association ,China National Medical Products Administration ,Astrazeneca ,Ascentage Pharma Group Inc ,University Of Texas Md Anderson Cancer Center ,Dana Farber Cancer Institute ,Md Anderson Cancer Center ,Major National ,National Reimbursement Drug List ,Embryonic Ectoderm Development ,University People Hospital ,European Hematology Association Hybrid Congress ,Poster Presentations ,Hematology Association Hybrid Congress ,Hybrid Congress ,Chief Medical Officer ,Overcomes Ponatinib ,Asciminib Resistance ,Heavily Pretreated Chronic Myeloid Leukemia ,Presentation Type ,Friday June ,Presenting Author ,Third Generation ,New Diagnosed Adult ,Nanfang Hospital ,Southern Medical ,Reported Outcomes ,Resistant Chronic Myeloid Leukemia Receiving ,Peking University People ,Novel Therapeutic Regimens ,Multiple Myeloma ,Immunoglobulin Light Chain ,Mayo Clinic ,Ectoderm Development ,Chronic Kidney ,Induced Hemoglobin ,Preclinical Models ,Ascentage Pharma Group ,Main Board ,Stock Exchange ,Hong Kong Limited ,Major National Rd Projects ,Major New Drug Projects ,New Drug Incubator ,Innovative Drug Programs ,Major Project ,Priority Review Designations ,Breakthrough Therapy Designations ,Drug Evaluation ,Reimbursement Drug List ,Orphan Drug Designation ,Fast Track Designation ,Orphan Designation ,Cancer Center ,